Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
Esophageal Squamous Cell Carcinoma|Locally Advanced Carcinoma
DRUG: Tislelizumab|DRUG: 5-FU|DRUG: cis Platinum
Incidence of translational treatment AE, Translational treatment-related AEs resulted in rates of surgery that were more than 30 days late or inoperable than originally planned, up to 2 years|MPR, The proportion of patients whose primary tumor cell residual was less than 10% in the total number of patients enrolled after transformation therapy, up to 2 years|pCR, Pathological complete response refers to that no tumor component or a small amount of carcinoma in situ component can be found on the horizontal line of pathological section after systemic treatment and surgical resection of the lesion., up to 2 years
R0 resection rate, The proportion of patients who completed R0 resection through 3 cycles of immunotherapy combined with chemotherapy in the total enrolled population.R0 finger resection margin under microscope was negative., up to 2 years|Disease-free Survival，DFS, The time from randomization to disease recurrence or death due to disease progression, up to 2 years
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.